Physician profile
Eric D Smith
NPI 1295736742
$20,187.11
in general payments reported to CMS, 2019-2025
67 companies · $4,301 in 2025
The $4,301 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,750 · 2020: $1,623 · 2021: $2,637 · 2022: $2,866 · 2023: $3,682 · 2024: $3,329 · 2025: $4,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,023.29 |
| Education | $288.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,110.63 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,628.75 | 2019-2025 | Vraylar, Qulipta, Linzess |
| Lilly USA, LLC | $1,119.85 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,089.80 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $1,082.86 | 2021-2025 | |
| Novo Nordisk INC | $983.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $813.58 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $798.71 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $783.26 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $660.56 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Lundbeck LLC | $658.89 | 2022-2025 | Rexulti |
| Amgen INC. | $623.32 | 2019-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $522.39 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $510.33 | 2022-2025 | Rexulti, Nuedexta |
| Kowa Pharmaceuticals America, INC. | $481.15 | 2019-2025 | Zoryve, Livalo, Seglentis |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $455.79 | 2019-2025 | |
| Radius Health, INC. | $413.98 | 2019-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $410.01 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $351.20 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $311.51 | 2019-2023 | Linzess |
| Amarin Pharma, INC. | $301.98 | 2019-2021 | |
| Astellas Pharma US INC | $255.89 | 2019-2024 | Myrbetriq, Veozah |
| Dexcom, INC. | $207.03 | 2021-2024 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $190.61 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $190.50 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Phathom Pharmaceuticals, INC. | $186.97 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $182.85 | 2022 | |
| Inari Medical, INC. | $180.23 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $177.53 | 2022-2024 | Caplyta |
| Esperion Therapeutics, INC. | $173.77 | 2020-2024 | Nexletol |
| Eisai INC. | $167.32 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $162.02 | 2020-2021 | |
| Abbott Laboratories | $159.55 | 2019-2023 | Freestyle Libre 3 |
| Actelion Pharmaceuticals US, INC. | $156.54 | 2023-2025 | Uptravi, Opsumit |
| Ardelyx, INC. | $133.87 | 2024 | Ibsrela |
| Sumitomo Pharma America, INC. | $120.27 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $112.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Optinose US, INC. | $111.39 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $109.23 | 2024-2025 | Zenpep |
| Tandem Diabetes Care, INC. | $101.88 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Axsome Therapeutics, INC. | $100.52 | 2023-2025 | Auvelity |
| Boston Scientific Corporation | $82.91 | 2022-2024 | Lux-Dx Insertable Cardiac Monitor |
| Allergan, INC. | $74.20 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $69.23 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $68.69 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $58.20 | 2021-2024 | Belbuca |
| Verona Pharma, INC. | $53.86 | 2025 | Ohtuvayre |
| Soleno Therapeutics, INC. | $52.94 | 2025 | Vykat Xr |
| Ironshore Pharmaceuticals INC. | $41.85 | 2024 | |
| Arbor Pharmaceuticals, INC. | $38.50 | 2019-2020 | |
| Mylan Specialty L.P. | $37.86 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $36.31 | 2025 | Fanapt |
| Globus Medical, INC. | $32.26 | 2025 | Senza |
| Supernus Pharmaceuticals, INC. | $27.85 | 2019 | |
| Nevro Corp. | $24.36 | 2024 | Senza |
| Almatica Pharma LLC | $21.59 | 2022 | |
| Organogenesis INC. | $20.22 | 2025 | Affinity |
| Circassia INC. | $19.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.14 | 2019 | |
| Averitas Pharma INC. | $17.92 | 2025 | Qutenza |
| Shire North American Group INC | $16.93 | 2019 | |
| Tolmar, INC. | $15.85 | 2024 | |
| Genentech USA, INC. | $15.10 | 2020 | |
| Medtronic Minimed, INC. | $14.61 | 2020 | |
| Axonics, INC. | $13.33 | 2021 | |
| Sanofi Pasteur INC. | $11.67 | 2020 | |
| Seqirus USA INC | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.